Sino Biopharm's Plexiform Neurofibromas Drug Gets Breakthrough Therapeutic Designation in China

MT Newswires Live

2025/10/15

Sino Biopharmaceutical's (HKG:1177) TQ-B3234 capsule has been included in the Breakthrough Therapy Designation (BTD) process by China's National Medical Products Administration, a Wednesday Hong Kong bourse filing said.

The drug is for the treatment of adult plexiform neurofibromas associated with symptomatic and inoperable neurofibromatosis type I.

This inclusion will expedite the drug launch process.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2575780450"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2575780450\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2575780450?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-15 21:18","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2575780450","market":"fut","top_or_hot":-1,"title":"Sino Biopharm's Plexiform Neurofibromas Drug Gets Breakthrough Therapeutic Designation in China","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/SBHMY\">Sino Biopharmaceutical</a>'s (HKG:1177) TQ-B3234 capsule has been included in the Breakthrough Therapy Designation (BTD) process by China's National Medical Products Administration, a Wednesday Hong Kong bourse filing said.</p><p>The drug is for the treatment of adult plexiform neurofibromas associated with symptomatic and inoperable neurofibromatosis type I.</p><p>This inclusion will expedite the drug launch process.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sino Biopharm's Plexiform Neurofibromas Drug Gets Breakthrough Therapeutic Designation in China</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSino Biopharm's Plexiform Neurofibromas Drug Gets Breakthrough Therapeutic Designation in China\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time smaller\">2025-10-15 21:18</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/SBHMY\">Sino Biopharmaceutical</a>'s (HKG:1177) TQ-B3234 capsule has been included in the Breakthrough Therapy Designation (BTD) process by China's National Medical Products Administration, a Wednesday Hong Kong bourse filing said.</p><p>The drug is for the treatment of adult plexiform neurofibromas associated with symptomatic and inoperable neurofibromatosis type I.</p><p>This inclusion will expedite the drug launch process.</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1521","symbol_name":"挪威政府全球養老基金持倉","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2575780450","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2575780450","pubTimestamp":1760534293,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Sino Biopharmaceutical's  TQ-B3234 capsule has been included in the Breakthrough Therapy Designation  process by China's National Medical Products Administration, a Wednesday Hong Kong bourse filing said.The drug is for the treatment of adult plexiform neurofibromas associated with symptomatic and inoperable neurofibromatosis type I.This inclusion will expedite the drug launch process.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1521":"挪威政府全球养老基金持仓","IE00BZ08YS42.EUR":"GUINNESS BEST OF CHINA \"C\" (EUR) ACC","BK1515":"抗疫概念","BK1589":"北水核心资产","IE00BZ08YT58.USD":"GUINNESS BEST OF CHINA \"C\" (USD) ACC","01177":"中国生物制药","00999":"小菜园","IE00BZ08YR35.GBP":"GUINNESS BEST OF CHINA \"C\" (GBP) ACC","BK1191":"制药"},"translate_title":"中国生物制药的丛状神经纤维瘤药物在中国获得突破性治疗资格","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"00999":0.6,"01177":1},"content_text":"Sino Biopharmaceutical's (HKG:1177) TQ-B3234 capsule has been included in the Breakthrough Therapy Designation (BTD) process by China's National Medical Products Administration, a Wednesday Hong Kong bourse filing said.The drug is for the treatment of adult plexiform neurofibromas associated with symptomatic and inoperable neurofibromatosis type I.This inclusion will expedite the drug launch process.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}